Takeda Pharmaceutical (TSE:4502) is expected to pay a larger dividend than last year at ¥100.00, which hints at consistent growth. The company's stocks have been rallying, indicating a strong relative strength amid mixed sentiments regarding its outlook. CEO, Christophe Weber, announced his resignation following a sustained drop in the company's shares. Despite this, the stocks have been upgraded to a 'strong buy'. Takeda has capped a solid year, with trends suggesting a rise in dividends in future. Amid global pharma stocks tumble, Takeda's resiliency has been noticed due to positive drug pipeline potential. In partnership with Protagonist Therapeutics, they announced encouraging Phase 3 Rusfertide results for Polycythemia Vera, reflecting its commitment to growth and innovation. Despite the impact of imminent tariff actions proposed by President Trump, Takeda has managed to complete a share repurchase program in May 2025. As the company tightens reins on early-stage investments, Morgan Stanley raised the target stock rating, endorsing its consistent performance and long-term potential. Prospective investors might find Takeda an interesting option as its Q3 performance marked by improved guidance indicates that the stocks may be undervalued.
Takeda Pharmaceutical Stocks News Analytics from Mon, 09 Jan 2017 08:00:00 GMT to Sat, 12 Jul 2025 07:24:45 GMT -
Rating 3
- Innovation 6
- Information 9
- Rumor -4
